Remdesivir

Summary

Remdesivir (CHEMBL4065616) is an approved small-molecule antiviral drug (ATC J05AB16); indicated across 9 conditions including severe acute respiratory syndrome and viral infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J05AB16
• Indications: 9 conditions
• Clinical trials: 84
• Chemistry: 602.6 Da · C27H35N6O8P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4065616
Name	Remdesivir
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	121304016
ChEBI	CHEBI:145994
ATC	J05AB16
Molecular formula	C27H35N6O8P
Molecular weight	602.6
InChIKey	RWWYLEGWBNMMLJ-YSOARWBDSA-N

SMILES: CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4

IUPAC name: 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate

ChEBI definition: A carboxylic ester resulting from the formal condensation of the carboxy group of N-[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]-L-alanine with the hydroxy group of 2-ethylbutan-1-ol. A broad-spectrum antiviral prodrug with potent in vitro antiviral activity against a diverse panel of RNA viruses such as Ebola virus, MERS-CoV and SARS-CoV. It is currently in Phase III clinical trials for the treatment of Covid-19 in adults.

Pharmacological roles (ChEBI): antiviral drug, prodrug, anticoronaviral agent.

Also known as: GS 5734, Gs-5734, GS-5734, Remdesivir, Veklury, REMDESIVIR, Remdesivir (GS-5734)

Patent coverage: 3,210 distinct patent families (6,642 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	CoV RNA-dependent RNA polymerase	Inhibition
		Inhibition

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Replicase polyprotein 1ab.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 10 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0DTD1	6.14	EC50	730	nM	CHEMBL_ACT_25615948
P0DTD1	5.98	EC50	1050	nM	CHEMBL_ACT_25615945
P0DTD1	5.95	EC50	1130	nM	CHEMBL_ACT_29311266
P0DTD1	5.92	IC50	1190	nM	CHEMBL_ACT_23254362
P0DTD1	5.87	EC50	1360	nM	CHEMBL_ACT_29173669
P0DTD1	5.81	IC50	1560	nM	CHEMBL_ACT_23254318
P0DTD1	5.81	EC50	1540	nM	CHEMBL_ACT_29173662
P0DTD1	5.79	IC50	1640	nM	CHEMBL_ACT_25099148
P0DTD1	5.71	EC50	1940	nM	CHEMBL_ACT_29311332
P0DTD1	5.51	IC50	3110	nM	CHEMBL_ACT_23254368

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
severe acute respiratory syndrome	4	MONDO:0005091	EFO:0000694
viral infectious disease	4	MONDO:0005108	EFO:0000763

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
pneumonia	3	MONDO:0005249	EFO:0003106
influenza	3	MONDO:0005812	EFO:0007328
Ebola hemorrhagic fever	2	MONDO:0005737	EFO:0007243
acute respiratory distress syndrome	2	MONDO:0006502	EFO:1000637
viral pneumonia	1	MONDO:0006012	EFO:0007541

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 84.

Phase distribution

Phase	Trials
PHASE3	34
PHASE2	17
Not specified	15
PHASE2/PHASE3	7
PHASE4	6
PHASE1/PHASE2	2
PHASE1	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06792214	PHASE4	RECRUITING	Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial
NCT04738045	PHASE4	UNKNOWN	Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients
NCT04779047	PHASE4	UNKNOWN	Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.
NCT04978259	PHASE4	UNKNOWN	SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients)
NCT05502081	PHASE4	COMPLETED	Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
NCT05911906	PHASE4	COMPLETED	An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
NCT02735707	PHASE3	RECRUITING	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT04483960	PHASE3	ACTIVE_NOT_RECRUITING	Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial
NCT07013474	PHASE3	RECRUITING	A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
NCT03719586	PHASE2/PHASE3	COMPLETED	Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
NCT04252664	PHASE3	SUSPENDED	A Trial of Remdesivir in Adults With Mild and Moderate COVID-19
NCT04257656	PHASE3	TERMINATED	A Trial of Remdesivir in Adults With Severe COVID-19
NCT04280705	PHASE3	COMPLETED	Adaptive COVID-19 Treatment Trial (ACTT)
NCT04292730	PHASE3	COMPLETED	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
NCT04292899	PHASE3	COMPLETED	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
NCT04315948	PHASE3	COMPLETED	Trial of Treatments for COVID-19 in Hospitalized Adults
NCT04321616	PHASE2/PHASE3	UNKNOWN	The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients
NCT04345419	PHASE2/PHASE3	COMPLETED	Remdesivir Efficacy in Coronavirus Disease
NCT04349410	PHASE2/PHASE3	COMPLETED	The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
NCT04351724	PHASE2/PHASE3	UNKNOWN	Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
NCT04401579	PHASE3	COMPLETED	Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
NCT04409262	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
NCT04431453	PHASE2/PHASE3	COMPLETED	Study of Remdesivir in Participants Below 18 Years Old With COVID-19
NCT04492475	PHASE3	COMPLETED	Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
NCT04501978	PHASE3	COMPLETED	ACTIV-3: Therapeutics for Inpatients With COVID-19
NCT04546581	PHASE3	COMPLETED	Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
NCT04575064	PHASE2/PHASE3	WITHDRAWN	An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
NCT04593940	PHASE3	COMPLETED	Immune Modulators for Treating COVID-19
NCT04640168	PHASE3	COMPLETED	Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
NCT04647669	PHASE3	UNKNOWN	World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
NCT04678739	PHASE3	COMPLETED	Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
NCT04693026	PHASE3	UNKNOWN	Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
NCT04694612	PHASE3	UNKNOWN	Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal
NCT04745351	PHASE3	TERMINATED	Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
NCT04784559	PHASE3	TERMINATED	Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
NCT04832880	PHASE3	UNKNOWN	Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)
NCT04843761	PHASE3	COMPLETED	ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
NCT04853901	PHASE3	COMPLETED	Remdesivir Efficacy In Management Of COVID-19 Patients
NCT04970719	PHASE3	WITHDRAWN	Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus
NCT05185284	PHASE3	COMPLETED	Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
NCT05780268	PHASE3	COMPLETED	LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780281	PHASE3	COMPLETED	VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780424	PHASE3	COMPLETED	BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780437	PHASE3	COMPLETED	AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780463	PHASE3	COMPLETED	MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780541	PHASE3	TERMINATED	PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT06729593	PHASE3	COMPLETED	Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT04488081	PHASE2	ACTIVE_NOT_RECRUITING	I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04746183	PHASE1/PHASE2	RECRUITING	AGILE (Early Phase Platform Trial for COVID-19)
NCT05041907	PHASE2	RECRUITING	Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
NCT05587894	PHASE2	RECRUITING	OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial
NCT06551844	PHASE2	RECRUITING	Adaptive Dengue Antiviral Platform Trial
NCT06817889	PHASE2	RECRUITING	Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
NCT06873633	PHASE2	RECRUITING	Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV
NCT07197164	PHASE2	RECRUITING	Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients
NCT02818582	PHASE2	COMPLETED	GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
NCT04321993	PHASE2	UNKNOWN	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
NCT04385719	PHASE2	COMPLETED	Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
NCT04391309	PHASE2	TERMINATED	COVID-19 and Anti-CD14 Treatment Trial
NCT04410354	PHASE2	TERMINATED	Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
NCT04539262	PHASE1/PHASE2	COMPLETED	Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
NCT04583956	PHASE2	COMPLETED	ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19
NCT04583969	PHASE2	COMPLETED	ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19
NCT04596839	PHASE2	COMPLETED	Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)
NCT04647695	PHASE2	UNKNOWN	IFN-beta 1b and Remdesivir for COVID19
NCT04988035	PHASE2	COMPLETED	ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19
NCT05925140	PHASE1	UNKNOWN	LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
NCT06860282	PHASE1	COMPLETED	A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects
NCT04560231	EARLY_PHASE1	UNKNOWN	Remdesivir in COVID-19 Lahore General Hospital
NCT03511118	Not specified	RECRUITING	Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
NCT04302766	Not specified	NO_LONGER_AVAILABLE	Expanded Access Remdesivir (RDV; GS-5734™)
NCT04323761	Not specified	APPROVED_FOR_MARKETING	Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
NCT04365725	Not specified	COMPLETED	Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections
NCT04492501	Not specified	COMPLETED	Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan
NCT04582266	Not specified	COMPLETED	PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US
NCT04669990	Not specified	UNKNOWN	Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study
NCT04727775	Not specified	COMPLETED	Antiviral Drugs on the Treatment of SARS-CoV-2
NCT04728880	Not specified	UNKNOWN	Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience
NCT04847622	Not specified	COMPLETED	Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
NCT04854837	Not specified	COMPLETED	Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis
NCT04865237	Not specified	COMPLETED	SARS-CoV-2 Human Challenge Characterisation Study
NCT04871633	Not specified	COMPLETED	Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore
NCT05024006	Not specified	COMPLETED	Public Health Emergency: SOLIDARITY TRIAL Philippines
NCT05222113	Not specified	COMPLETED	OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).